Literature DB >> 3569188

Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients.

A A Nanji, S W French, J B Freeman.   

Abstract

We evaluated the change in serum alanine aminotransferase (ALT; EC 2.6.1.2) to serum aspartate aminotransferase (AST; EC 2.6.1.; ALT/AST) ratio with the degree of fatty liver in morbidly obese patients. A total of 31 patients were included in the study. Fatty liver was graded as 0 to 4+. The mean and SD of AST and ALT were not significantly different between groups of patients with various grades of fatty liver. There was, however, a significant correlation between the ALT/AST ratio and the degree of fatty infiltration of the liver. This, we believe, implies damage mainly to the plasma membrane allowing loss of cytoplasmic enzymes rather than loss of mitochondrial enzymes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3569188     DOI: 10.1159/000469304

Source DB:  PubMed          Journal:  Enzyme        ISSN: 0013-9432


  15 in total

Review 1.  The de ritis ratio: the test of time.

Authors:  Mona Botros; Kenneth A Sikaris
Journal:  Clin Biochem Rev       Date:  2013-11

2.  Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: the Framingham Heart Study.

Authors:  Stacy A Porter; Alison Pedley; Joseph M Massaro; Ramachandran S Vasan; Udo Hoffmann; Caroline S Fox
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-15       Impact factor: 8.311

3.  Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonographic characteristics.

Authors:  Georgi Kirovski; Doris Schacherer; Hella Wobser; Hanna Huber; Christoph Niessen; Catrin Beer; Jürgen Schölmerich; Claus Hellerbrand
Journal:  Int J Clin Exp Med       Date:  2010-07-15

4.  Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study.

Authors:  Yuichiro Eguchi; Hideyuki Hyogo; Masafumi Ono; Toshihiko Mizuta; Naofumi Ono; Kazuma Fujimoto; Kazuaki Chayama; Toshiji Saibara
Journal:  J Gastroenterol       Date:  2012-02-11       Impact factor: 7.527

5.  Gryllus bimaculatus extract ameliorates high-fat diet-induced hyperglycemia and hyperlipidemia by inhibiting hepatic lipogenesis through AMPK activation.

Authors:  Kyong Kim; Eun-Young Park; Dong Jae Baek; Yoon Sin Oh
Journal:  Food Sci Biotechnol       Date:  2022-06-28       Impact factor: 3.231

6.  Spinal cord injury causes chronic liver pathology in rats.

Authors:  Andrew D Sauerbeck; J Lukas Laws; Veera V R Bandaru; Phillip G Popovich; Norman J Haughey; Dana M McTigue
Journal:  J Neurotrauma       Date:  2014-10-21       Impact factor: 5.269

7.  Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease.

Authors:  Wolfram Goessling; Joseph M Massaro; Ramachandran S Vasan; Ralph B D'Agostino; R Curtis Ellison; Caroline S Fox
Journal:  Gastroenterology       Date:  2008-09-20       Impact factor: 22.682

8.  Development and Validation of the Framingham Steatosis Index to Identify Persons With Hepatic Steatosis.

Authors:  Michelle T Long; Alison Pedley; Lisandro D Colantonio; Joseph M Massaro; Udo Hoffmann; Paul Muntner; Caroline S Fox
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-01       Impact factor: 11.382

9.  A predictive model for the diagnosis of non-alcoholic fatty liver disease based on an integrated machine learning method.

Authors:  Xuefeng Ma; Chao Yang; Kun Liang; Baokai Sun; Wenwen Jin; Lizhen Chen; Mengzhen Dong; Shousheng Liu; Yongning Xin; Likun Zhuang
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

10.  Alanine aminotransferase/aspartate aminotransferase ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults.

Authors:  Ryuichi Kawamoto; Katsuhiko Kohara; Tomo Kusunoki; Yasuharu Tabara; Masanori Abe; Tetsuro Miki
Journal:  Cardiovasc Diabetol       Date:  2012-10-01       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.